Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma
Abstract Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). However, the long-...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-88813-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862208054951936 |
|---|---|
| author | Zhaosong Xue Ming Yao Kang Chen Taiyun Huang Jianjun Li Jian Chen Fei Huang Yubin Huang Xiaoyong Cai Yihe Yan |
| author_facet | Zhaosong Xue Ming Yao Kang Chen Taiyun Huang Jianjun Li Jian Chen Fei Huang Yubin Huang Xiaoyong Cai Yihe Yan |
| author_sort | Zhaosong Xue |
| collection | DOAJ |
| description | Abstract Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). However, the long-term survival outcomes remain largely unexplored. This study focused on a cohort of consecutive patients who underwent triple therapy for initially unresectable HCC at the authors’ hospital between January 2020 and December 2022. Specifically, patients who exhibited a positive response to triple therapy and fulfilled the criteria for hepatectomy were selected for liver resection. Additionally, investigation assessed association between clinical factors and successful achievement of conversion resection, as well as postoperative recurrence. The study cohort comprised 79 patients, among whom 20 individuals (25.3%) underwent R0 resection subsequent to the initiation of triple therapy. Notably, patients without extrahepatic disease and those who exhibited a radiographic response to triple therapy were more likely to be eligible for curative resection. Importantly, hepatectomy independently associated with a favorable overall survival (HR, 0.388; 95% CI, 0.177–0.847; P = 0.017). Other independent risk factors related to overall survival contained extrahepatic metastasis (HR, 2.152; 95% CI, 1.076–4.302; P = 0.030), tumor number ≥ 4 (HR, 2.058; 95% CI, 1.001–4.234; P = 0.049) and radiological remission (HR, 0.233; 95% CI, 0.071–0.768; P = 0.017). For the 20 patients who underwent surgery, 12-month recurrence-free survival and overall survival rates were respectively 43.3% and 66.6%. The triple therapy demonstrated favorable prognostic outcomes and manageable safety profiles in patients with initially unresectable HCC. |
| format | Article |
| id | doaj-art-996c409e87e745deb00e0d5d1459adff |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-996c409e87e745deb00e0d5d1459adff2025-02-09T12:36:52ZengNature PortfolioScientific Reports2045-23222025-02-0115111010.1038/s41598-025-88813-8Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinomaZhaosong Xue0Ming Yao1Kang Chen2Taiyun Huang3Jianjun Li4Jian Chen5Fei Huang6Yubin Huang7Xiaoyong Cai8Yihe Yan9Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityDepartment of General Surgery, The Second Affiliated Hospital of Guangxi Medical UniversityAbstract Combining local interventions with tyrosine kinase inhibitors (TKIs) plus anti-PD-1 antibodies in a triple therapy has demonstrated remarkable anti-tumor efficacy and facilitated conversion resection in patients with initially unresectable hepatocellular carcinoma (HCC). However, the long-term survival outcomes remain largely unexplored. This study focused on a cohort of consecutive patients who underwent triple therapy for initially unresectable HCC at the authors’ hospital between January 2020 and December 2022. Specifically, patients who exhibited a positive response to triple therapy and fulfilled the criteria for hepatectomy were selected for liver resection. Additionally, investigation assessed association between clinical factors and successful achievement of conversion resection, as well as postoperative recurrence. The study cohort comprised 79 patients, among whom 20 individuals (25.3%) underwent R0 resection subsequent to the initiation of triple therapy. Notably, patients without extrahepatic disease and those who exhibited a radiographic response to triple therapy were more likely to be eligible for curative resection. Importantly, hepatectomy independently associated with a favorable overall survival (HR, 0.388; 95% CI, 0.177–0.847; P = 0.017). Other independent risk factors related to overall survival contained extrahepatic metastasis (HR, 2.152; 95% CI, 1.076–4.302; P = 0.030), tumor number ≥ 4 (HR, 2.058; 95% CI, 1.001–4.234; P = 0.049) and radiological remission (HR, 0.233; 95% CI, 0.071–0.768; P = 0.017). For the 20 patients who underwent surgery, 12-month recurrence-free survival and overall survival rates were respectively 43.3% and 66.6%. The triple therapy demonstrated favorable prognostic outcomes and manageable safety profiles in patients with initially unresectable HCC.https://doi.org/10.1038/s41598-025-88813-8 |
| spellingShingle | Zhaosong Xue Ming Yao Kang Chen Taiyun Huang Jianjun Li Jian Chen Fei Huang Yubin Huang Xiaoyong Cai Yihe Yan Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma Scientific Reports |
| title | Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma |
| title_full | Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma |
| title_fullStr | Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma |
| title_full_unstemmed | Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma |
| title_short | Real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma |
| title_sort | real world study on combining local interventions with systemic therapy in unresectable hepatocellular carcinoma |
| url | https://doi.org/10.1038/s41598-025-88813-8 |
| work_keys_str_mv | AT zhaosongxue realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT mingyao realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT kangchen realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT taiyunhuang realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT jianjunli realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT jianchen realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT feihuang realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT yubinhuang realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT xiaoyongcai realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma AT yiheyan realworldstudyoncombininglocalinterventionswithsystemictherapyinunresectablehepatocellularcarcinoma |